TMO vs. AZN, NVS, ABT, PFE, AMGN, ISRG, SYK, ELV, SNY, and ABBV
Should you be buying Thermo Fisher Scientific stock or one of its competitors? The main competitors of Thermo Fisher Scientific include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), Amgen (AMGN), Intuitive Surgical (ISRG), Stryker (SYK), Elevance Health (ELV), Sanofi (SNY), and AbbVie (ABBV). These companies are all part of the "medical" sector.
Thermo Fisher Scientific (NYSE:TMO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.
Thermo Fisher Scientific has a net margin of 14.20% compared to AstraZeneca's net margin of 13.30%. AstraZeneca's return on equity of 30.34% beat Thermo Fisher Scientific's return on equity.
Thermo Fisher Scientific received 998 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 81.11% of users gave Thermo Fisher Scientific an outperform vote while only 58.06% of users gave AstraZeneca an outperform vote.
89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Thermo Fisher Scientific pays an annual dividend of $1.56 per share and has a dividend yield of 0.3%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.6%. Thermo Fisher Scientific pays out 10.0% of its earnings in the form of a dividend. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Thermo Fisher Scientific has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
In the previous week, Thermo Fisher Scientific had 12 more articles in the media than AstraZeneca. MarketBeat recorded 49 mentions for Thermo Fisher Scientific and 37 mentions for AstraZeneca. Thermo Fisher Scientific's average media sentiment score of 0.56 beat AstraZeneca's score of 0.45 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.
Thermo Fisher Scientific currently has a consensus target price of $606.76, suggesting a potential upside of 5.78%. AstraZeneca has a consensus target price of $81.00, suggesting a potential upside of 7.76%. Given AstraZeneca's higher probable upside, analysts plainly believe AstraZeneca is more favorable than Thermo Fisher Scientific.
Thermo Fisher Scientific has higher earnings, but lower revenue than AstraZeneca. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
Summary
Thermo Fisher Scientific beats AstraZeneca on 14 of the 20 factors compared between the two stocks.
Get Thermo Fisher Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Thermo Fisher Scientific Competitors List
Related Companies and Tools
